Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EPS (Basic) for 10 consecutive years, with -$1.28 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 7.25% to -$1.28 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.83, a 7.75% increase, with the full-year FY2025 number at -$5.83, up 7.31% from a year prior.
  • EPS (Basic) was -$1.28 for Q4 2025 at Ultragenyx Pharmaceutical, up from -$1.81 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$1.08 in Q3 2021 to a low of -$3.5 in Q3 2022.
  • A 5-year average of -$1.86 and a median of -$1.81 in 2021 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 530.95% in 2021, then surged 37.22% in 2024.
  • Ultragenyx Pharmaceutical's EPS (Basic) stood at -$1.79 in 2021, then fell by 20.67% to -$2.16 in 2022, then surged by 33.33% to -$1.44 in 2023, then increased by 4.17% to -$1.38 in 2024, then rose by 7.25% to -$1.28 in 2025.
  • Per Business Quant, the three most recent readings for RARE's EPS (Basic) are -$1.28 (Q4 2025), -$1.81 (Q3 2025), and -$1.17 (Q2 2025).